Indometacin farnesil
Indometacin farnesil is a pharmaceutical compound recognized by its INN. Acting as a prodrug, it serves as a precursor to the more widely recognized non-steroidal anti-inflammatory drug (NSAID) known as indometacin.
Overview[edit]
The primary rationale behind the creation of indometacin farnesil was to circumvent some of the adverse effects commonly associated with indometacin. This was achieved by esterifying the carboxyl group present on indometacin using farnesol, a process that can reduce the potential for certain side-effects.
Approval and Availability[edit]
Japan[edit]
Indometacin farnesil received its initial approval in Japan in 1991. It is commercially available in the country under the trade name Infree.
Indonesia[edit]
In addition to Japan, indometacin farnesil is also available in Indonesia. Here, the medication can be found under the trade name Dialon.
Pharmacological Mechanism[edit]
As a prodrug, indometacin farnesil is biologically inactive in its administered form. Once inside the body, however, it is metabolized to release the active NSAID, indometacin. This transformation allows for the therapeutic effects of indometacin to be realized, while the esterification with farnesol aims to mitigate the drug's side-effects.
See Also[edit]
External links[edit]
| Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA) |
|---|
Drug groups | Encyclopedia | Dictionary | Cancer drugs | OTC | Alternative meds | Drugs | Medications A-Z | FDA approved products | Portal:Pharmacology
| Major chemical drug groups | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
